+

PE20091104A1 - Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo - Google Patents

Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo

Info

Publication number
PE20091104A1
PE20091104A1 PE2008002112A PE2008002112A PE20091104A1 PE 20091104 A1 PE20091104 A1 PE 20091104A1 PE 2008002112 A PE2008002112 A PE 2008002112A PE 2008002112 A PE2008002112 A PE 2008002112A PE 20091104 A1 PE20091104 A1 PE 20091104A1
Authority
PE
Peru
Prior art keywords
antigen
protein
vsv
virus
genetically modified
Prior art date
Application number
PE2008002112A
Other languages
English (en)
Inventor
Narender Kumar Kalyan
Irina Yurgelonis
Roger Michael Hendry
Mark Cutler
Kristen Syvertsen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20091104A1 publication Critical patent/PE20091104A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20264—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REFERIDO A UN VIRUS DE LA ESTOMATITIS VESICULAR (VSV) GENETICAMENTE MODIFICADO QUE TIENE POR LO MENOS UNA MUTACION DE AMINOACIDO EN UNA REGION QUE CORRESPONDE A POR LO MENOS UNA DE LAS SIGUIENTES POSICIONES: 119 O 142 DE LA PROTEINA M; 109, 224, 438, 477, O 481 DE LA PROTEINA G; 205, 220 O 1450 DE LA PROTEINA L. ADEMAS EL ADN QUE CODIFICA EL VSV COMPRENDE UN ACIDO NUCLEICO QUE CODIFICA A POR LO MENOS UN ANTIGENO HETEROLOGO SELECCIONADO DEL GRUPO QUE CONSISTE EN UN ANTIGENO DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA (VIH), UN ANTIGENO HTLV, UN ANTIGENO SIV, UN ANTIGENO RSV, UN ANTIGENO PIV, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION INMUNOGENICA Y A UN METODO DE PRODUCCION QUE COMPRENDE EL PASO EN SERIE DE UN VSV EN UNA LINEA CELULAR DE MAMIFERO CONTINUA A UNA BAJA MULTIPLICIDAD DE INFECCION (MOI) QUE VARIA DESDE APROXIMADAMENTE 0.001 A APROXIMADAMENTE 0.1 UNIDADES FORMADORAS DE PLACA (PFU)/ml DURANTE POR LO MENOS 5-15 PASADAS, EN DONDE EL VIRUS TIENE UN TITULO DE 1 X 106 PFU/ml. SIENDO UTIL PARA DESPLEGAR LA ANTIGENICIDAD E INMUNOGENICIDAD DE UN ANTIGENO DE PATOGENO HUMANO U OTROS ANTIGENOS DE INTERES
PE2008002112A 2007-12-21 2008-12-18 Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo PE20091104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1586807P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
PE20091104A1 true PE20091104A1 (es) 2009-07-18

Family

ID=40791563

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002112A PE20091104A1 (es) 2007-12-21 2008-12-18 Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo

Country Status (17)

Country Link
US (1) US20090175906A1 (es)
EP (1) EP2224952A2 (es)
JP (1) JP2011507523A (es)
KR (1) KR20110004354A (es)
CN (1) CN101981182A (es)
AR (1) AR069883A1 (es)
AU (1) AU2008340319A1 (es)
BR (1) BRPI0821558A2 (es)
CA (1) CA2710350A1 (es)
CL (1) CL2008003794A1 (es)
CO (1) CO6290704A2 (es)
IL (1) IL206462A0 (es)
PE (1) PE20091104A1 (es)
RU (1) RU2010124788A (es)
TW (1) TW200932259A (es)
WO (1) WO2009082664A2 (es)
ZA (1) ZA201005182B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
WO2012170814A1 (en) * 2011-06-08 2012-12-13 The Ohio State University Norovirus immunogens and related materials and methods
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
GB201614050D0 (en) * 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
WO2018226506A1 (en) * 2017-06-05 2018-12-13 Arizona Board Of Regents On Behalf Of Arizona State University Reducing the toxicity of agrobacterium endotoxin
EP3706750A1 (en) * 2017-11-06 2020-09-16 RAPT Therapeutics, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CN110577585A (zh) * 2018-06-07 2019-12-17 中国医学科学院基础医学研究所 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用
WO2020018705A1 (en) 2018-07-17 2020-01-23 Yale University Methods for treatment of cancer using chikungunya-vsv chimeric virus
WO2020029274A1 (zh) * 2018-08-10 2020-02-13 苏州奥特铭医药科技有限公司 一种减毒棒状病毒的制备方法及应用
CN110305850A (zh) * 2019-05-15 2019-10-08 苏州奥特铭医药科技有限公司 一种利用293细胞生产制备溶瘤病毒的方法
CA3185332A1 (en) * 2020-06-03 2021-12-09 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
WO2022092779A1 (ko) * 2020-10-29 2022-05-05 에스케이바이오사이언스 주식회사 사스-코로나바이러스-2 항원 물질을 포함하는 바이럴 벡터 및 이의 이용
WO2023051607A1 (zh) * 2021-09-29 2023-04-06 上海行深生物科技有限公司 病毒培养方法
CN117065052A (zh) * 2022-05-16 2023-11-17 上海行深生物科技有限公司 递送自复制rna分子的方法
CN115725657B (zh) * 2022-09-16 2024-06-04 中国科学院广州生物医药与健康研究院 一种节段化的水泡性口炎病毒载体及其制备方法和应用
CN115948352A (zh) * 2022-11-29 2023-04-11 浙江迪福润丝生物科技有限公司 一种水泡性口炎病毒的致弱方法及致弱病毒株和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE257175T1 (de) * 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6673572B2 (en) * 1998-06-03 2004-01-06 Wyeth Holdings Corporation Methods for rescue of RNA viruses
DE60041210D1 (de) * 1999-09-17 2009-02-05 Wellstat Biologics Corp Onkolytisches Virus
CA2528002A1 (en) * 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded rna viruses from cdna
DK1756287T3 (en) * 2004-04-09 2015-03-23 Wyeth Llc A synergistic attenuation of vesicular stomatitis virus, vectors, and immunogenic compositions thereof thereof
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej

Also Published As

Publication number Publication date
CN101981182A (zh) 2011-02-23
WO2009082664A8 (en) 2009-09-17
AR069883A1 (es) 2010-02-24
TW200932259A (en) 2009-08-01
JP2011507523A (ja) 2011-03-10
BRPI0821558A2 (pt) 2015-11-03
RU2010124788A (ru) 2012-01-27
KR20110004354A (ko) 2011-01-13
CO6290704A2 (es) 2011-06-20
CL2008003794A1 (es) 2009-03-20
WO2009082664A2 (en) 2009-07-02
WO2009082664A3 (en) 2009-11-26
AU2008340319A1 (en) 2009-07-02
IL206462A0 (en) 2010-12-30
EP2224952A2 (en) 2010-09-08
CA2710350A1 (en) 2009-07-02
US20090175906A1 (en) 2009-07-09
ZA201005182B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
PE20091104A1 (es) Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
CY1121323T1 (el) Αντισωματα εξουδετερωσης του ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
PE20250757A1 (es) Muteinas de interleucina 21 y metodos de tratamiento
US20240374703A1 (en) Immunogenic compositions and uses thereof
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
DK1939281T4 (da) Immortaliserede andecellelinjer til virusproduktion
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
AR059772A1 (es) Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
HRP20110320T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
PE20250020A1 (es) Composicion inmunogenica contra la influenza
MX2022015734A (es) Proteinas de exotoxina a modificadas.
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
ATE539767T1 (de) Adjuvans auf basis von polyinosinsäure/polycytidylsäure
MX2022005327A (es) Tintes y composiciones que contienen ciclooctatetraeno..
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
Ruprecht et al. Mucosal antibodies: defending epithelial barriers against HIV-1 invasion
ES2561483T3 (es) Antígenos mutantes de GAS57 y anticuerpos de GAS57
EA200970731A1 (ru) Рекомбинантные антигены цитомегаловируса человека (hcmv)
WO2006020480A3 (en) Adenoviral vector compositions

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载